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Abstract
Objective Sun exposure and sensitivity, including pig-
mentation, are associated with risk for non-Hodgkin
lymphoma (NHL). One variant in the immune regulatory
factor 4 (IRF4) gene (rs12203592) is associated with
pigmentation, and a different IRF4 variant (rs12211228)
is associated with NHL risk. We evaluated the
independent roles of these IRF4 polymorphisms and sun
sensitivity in mediating NHL risk and explored whether
they are confounded or modiﬁed by each other.
Methods Genotyping of tag single nucleotide polymor-
phisms (SNPs) in the IRF4 gene was conducted in 990
NHL cases and 828 controls from a multi-center US
study. Measures of sun sensitivity and exposure were
ascertained from computer-assisted personal interviews.
We used logistic regression to compute odds ratios (OR)
and 95% conﬁdence intervals (CI) for NHL in relation to
sun exposures, sun exposures in relation to IRF4 geno-
types, and NHL in relation to sun exposures. We further
assessed the effects of sun exposures in relation to IRF4
genotypes.
Results As previously reported, we found signiﬁcant
associations between IRF4 rs12211228 and NHL and
between hair and eye color and NHL. The IRF4
rs12203592 polymorphism (CT/TT genotype) was statis-
tically signiﬁcantly associated with eye color and particu-
larly with hair color (ORLight Blonde = 0.24, 95%
CI = 0.11–0.50, overall Chi square p = 0.0002). Analysis
of joint effects between eye and hair color with the IRF4
rs12203592 SNP did not reveal statistically signiﬁcant
p-interactions although NHL risk did decline with lighter
hair color and presence of the variant IRF4 rs12203592
allele, compared to those without a variant allele and with
black/brown hair color.
Conclusions Our data do not statistically support a joint
effect between IRF4 and sun sensitivity in mediating risk
for NHL. Further evaluation of joint effects in other and
larger populations is warranted.
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Introduction
Non-Hodgkin lymphomas (NHL) represent a heteroge-
neous group of cancers arising from lymphocytes for which
the etiology remains largely unclear. While the major
known risk factor for developing NHL is severe immuno-
deﬁciency [1], the increased NHL risk among those with a
family history of hematopoietic disease [2–5] suggests an
important role for genetic susceptibility in NHL etiology.
Investigations of germline genetic variation in large epi-
demiologic case–control studies have identiﬁed potentially
relevant loci that may play a role in modulating risk for
NHL [6, 7].
A recent pooled analysis of three large population-based
NHL case–control studies that included the present study
found a signiﬁcant association between a polymorphism in
the IRF4 gene, rs12211228 and NHL risk [8]. The IRF4
gene (also known as MUM1) encodes a protein that is a
member of the interferon regulatory factor family [9–12].
IRF4 is a B-cell proliferation and differentiation protein
essential for class switch recognition and antibody matu-
ration [13, 14] and is often found abnormally expressed in
B cell lymphomas [15]. In addition to serving as a marker
for lymphoid tumors such as NHL, IRF4 has also been
reported to act as a potential marker for melanoma [16].
A recent large genome-wide association study demon-
strated a convincing association between a different poly-
morphism of the IRF4 gene, rs12203592, and pigmentation
phenotypes, most notably hair color [17]. This IRF4 SNP
was also shown to be associated with skin color, eye color,
and a measure of skin tanning response to sunlight. This
report was the ﬁrst to suggest a link between a particular
IRF4 locus and human pigmentation, though the mecha-
nism for the involvement of this immune regulatory gene in
determining hair color and other pigmentation phenotypes
remains unclear.
Interestingly, sun sensitivity and sun exposure have
previously been linked with NHL. Hartge et al. [18] pre-
viously showed a gradient of decreasing NHL risk with
increasingly light eye color, one pigmentation phenotype
believed to act as a marker of increased sun sensitivity.
This relationship between risk for NHL and sun sensitivity
and exposure is further supported by recent work from the
International Lymphoma Epidemiology Consortium (In-
terLymph)[19], where a pooled analysis of ten case–control
studies of NHL showed a signiﬁcant decrease in NHL risk
with increasing recreational sun exposure.
In order to clarify the roles of these two IRF4 poly-
morphisms and sun sensitivity in mediating NHL risk and
to determine if their respective associations with NHL are
confounded or modiﬁed by each other, we used a large US
multi-center case–control study of NHL to evaluate the
relationship between IRF4 polymorphisms and markers of
sun sensitivity and sun exposure and their roles in deter-
mining risk for non-Hodgkin lymphoma.
Materials and methods
Study population
The study population has been described previously in
detail [3]. Brieﬂy, we included 1,321 newly diagnosed non-
Hodgkin lymphoma cases identiﬁed in four Surveillance,
Epidemiology, and End Results (SEER) registries (Iowa;
Detroit, MI; Los Angeles, CA; and Seattle, WA) between 1
July 1998 and 30 June 2000. Subjects were between the
ages of 20 and 74 and had no evidence of HIV infection. A
total of 1,057 population controls were identiﬁed by ran-
dom digit dialing (under 65 years old) and from Medicare
eligibility ﬁles (65 years and older). Overall participation
rates were 76% in cases and 52% in controls; overall
response rates were 59 and 44%, respectively. Written
informed consent was obtained from each participant
before interview. This study was approved by the institu-
tional review boards at the NIH and at each participating
SEER site (Iowa, Detroit, LA, and Seattle).
All study participants were asked to provide a venous
blood or mouthwash buccal cell sample. We obtained
blood samples from 1,172 (89%) cases (773 blood, 399
buccal) and 982 (93%) controls (668 blood, 314 buccal).
Genotype frequencies were equivalent for individuals who
provided blood compared with buccal cells.
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Each SEER registry provided non-Hodgkin lymphoma
pathology and subtype information derived from abstracted
reports by the local diagnosing pathologist. All cases were
histologically conﬁrmed and coded according to the
International Classiﬁcation of Diseases for Oncology, 2nd
Edition (ICD-O-2) [20] and updated to the World Health
Organization classiﬁcation/ICD-O-3 [21].
Questionnaire data
The study used a split-sample design to investigate multi-
ple etiologic risk factors in detail without overburdening
the participants. A core set of questions was given to all
respondents, and the remainder of questions were given to
participants in either Group A (all African-American par-
ticipants and 50% of non-African-American participants)
or Group B (50% of non-African-American participants).
Prior to the in-person interview, participants were mailed
a form for listing residential and job history and either a
family and medical history questionnaire (Group A) or a
diet and lifestyle questionnaire (Group B). During the
home visit, a trained interviewer administered a computer-
assisted personal interview (CAPI) that included core
questions on demographics, height and weight, occupa-
tional history, pesticide exposure, hair color, and hair dye
use. The Group A CAPI also included an extended medical
history and use of illicit drugs, while the Group B CAPI
included an abbreviated medical history, cell phone use,
allergies, hobbies, eye color, skin complexion, and sun
sensitivity/exposure.
Sun sensitivity and exposure. During the interview, we
asked participants to estimate how many hours they spent
in the sun during the summer in the middle of the day
(10:00 AM–4:00 PM). We asked separately for weekdays
and weekend days and separately for speciﬁc periods of
their lives including teenage years, twenties, thirties, and
the most recent decade. In the analysis, we estimated typ-
ical weekly exposure to strong sunlight as a weighted
average of weekend and weekday values. We also asked
about the use of sun lamps or tanning booths, the typical
number of months per year they had a tan, pigmentation
characteristics including eye color and skin complexion,
and some common measures of skin response to sunlight,
including sun rashes and typical reaction to ﬁrst hour of sun
with no tan and no sunburn.
DNA extraction and genotyping
Study participants who did not provide a biologic speci-
men, did not have sufﬁcient material for DNA extraction or
sufﬁcient DNA for genotyping, or whose genotyped sex
was discordant from the questionnaire data were excluded
from this analysis. As previously described [22], DNA was
extracted from blood clots or buffy coats (BBI Biotech,
Gaithersburg, MD) using Puregene Autopure DNA
extraction kits (Gentra Systems, Minneapolis, MN). DNA
was extracted from buccal cell samples by phenol–chlo-
roform extraction methods [23].
We selected 15 tag single nucleotide polymorphisms
(SNPs) in the IRF4 gene as previously described [8]; these
included the two a priori SNPs of interest—rs12211228
and rs12203592. Genotyping was conducted at the
National Cancer Institute Core Genotyping Facility
(Advanced Technology Center, Gaithersburg, MD) using a
custom-designed GoldenGate assay (Illumina, www.
illumina.com). Sequence data and assay conditions are
provided at http://snp500cancer.nci.nih.gov [24]. SNP
completion rates were[95% for the 15 IRF4 SNPs. Forty
replicate samples from two blood donors each and dupli-
cate samples from 100 participants processed in an iden-
tical fashion were interspersed for all assays and blinded
from the laboratory. The 15 IRF4 SNPs were[95% con-
cordant in the quality control samples. We excluded sam-
ples with a low completion rate (\90%; 11 cases, 6
controls). Hardy–Weinberg Equilibrium (HWE) was
observed in the control group for all IRF4 SNPs (assessed
separately for non-Hispanic Caucasians and blacks).
The ﬁnal analytic population consisted of 990 cases and
828 controls.
Statistical analysis
IRF4 and NHL. We calculated odds ratios (OR) and 95%
conﬁdence intervals (95% CI) as an estimate of relative
risk for non-Hodgkin lymphoma outcomes using dichoto-
mous (overall NHL) and polytomous (NHL subtypes)
unconditional logistic regression models with the homo-
zygous wild-type genotype as the referent group. We
conducted stratiﬁed analyses by age (\60 and C60 years),
sex (male and female), and race (non-Hispanic Caucasians
and blacks). Finding no signiﬁcant differences in the risk
estimates by each of these three strata, we pooled the
results and adjusted for the study design variables: age
(\50, 50–59, 60–69, 70?), sex, race/ethnicity (non-His-
panic Caucasian, black, other), and study site (Iowa, Los
Angeles, Seattle, Detroit). We calculated the p for trend
based on the three-level ordinal variable (0, 1, 2) of
homozygote wild-type, heterozygote, and homozygote
variant. In addition to the individual risk estimates for each
genotype, we evaluated the dominant model with homo-
zygote wild-type as the referent group for comparison with
heterozygotes and homozygote variants combined.
Sun sensitivity and NHL. In order to assess the associ-
ation between the ordinal pigmentation and sun exposure
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using dichotomous and polytomous unconditional logistic
regression models for NHL overall and NHL subtypes,
respectively. We also calculated the p for trend value for
linear trend in regression based on the categorical variables
(0, 1, 2, etc.) for each level of exposure (e.g., for eye color:
dark brown (0), light brown [1], hazel (2), blue (3), green/
blue-green (4)). For eye and hair color, skin complexion,
reaction to ﬁrst sun of the season, and hours in the mid-day
sun in the last 10 years, the category corresponding to the
lowest level of sun sensitivity or exposure was used as the
referent category. All analyses were conducted both crude
and adjusted for the study design variables age, race/eth-
nicity, sex, and study site. We note that we also included
adjustment for education as a surrogate for SES; though
education was slightly associated with sunlight exposure,
additional adjustment for education did not appreciably
alter the risk estimates for NHL (\10%) and we therefore
retained the most parsimonious model in our ﬁnal model
which excluded education. Secondary analyses restricted to
subjects with genotype data and non-Hispanic Caucasian
subjects with genotype data were also performed to assess
consistency across population subgroups (adjusted for age,
sex, and study site).
IRF4 and sun sensitivity. Among controls, we used
logistic regression adjusted for age, sex, and study site to
model the association between pigmentation or sun expo-
sure and IRF4 genotypes. For each exposure category, the
OR and 95% CI were calculated for the heterozygotes and
homozygous variants using the wild-type homozygotes as
the referent group. We also calculated the p for trend across
the genotypes in each exposure category to assess likeli-
hood of that exposure category with each additional minor
allele. We also conducted this analysis restricted to non-
Hispanic Caucasians in the control group due to known
variation in eye color, hair color, and other phenotypic
features across race groups.
Joint effects of IRF4 and sun sensitivity. For each sun
sensitivity exposure, we calculated the OR and 95% CI for
NHL using a common referent group and also stratiﬁed by
IRF4 genotype under the dominant model, combining
heterozygotes and homozygous variants. We calculated the
p-value for interaction for each exposure and IRF4 SNP for
NHL risk based on the scored variable for each risk factor
and for the genotype. In these calculations, we scored the
genotype using a two-level categorization to assess risk for
the presence of a variant allele. Statistical signiﬁcance for
interaction was evaluated with the Wald test in models that
included a product term for the scored risk factor and the
scored genotype. The category corresponding to the lowest
level of sun sensitivity or sun exposure was used as the
referent group for each exposure. Analyses were conducted
using SAS version 9.1 (SAS Institute, Cary, NC).
Results
Table 1 shows selected characteristics of the NCI-SEER
study population. Brieﬂy, the majority of cases and con-
trols were non-Hispanic Caucasians, cases were slightly
younger than controls, and there were slightly more men
than women in both cases and controls. Cases and controls
were distributed roughly evenly into interview groups A
and B. The most common NHL subtypes were diffuse large
B-cell lymphoma (DLBCL) and follicular lymphoma.
IRF4 and NHL. Fifteen SNPs in the IRF4 gene were
evaluated for associations with non-Hodgkin lymphoma
(Supplementary Table 1). We observed a signiﬁcant
decrease in risk for NHL with the IRF4 SNP rs12211228
(ORCG = 0.81, 95% CI = 0.65–1.00; ORCC = 0.76, 95%
CI = 0.35–1.65; p-trend = 0.04; Table 2). Results were
consistent when restricted to non-Hispanic Caucasian
subjects. We observed no statistically signiﬁcant associa-
tion between the IRF4 SNP rs12203592 and NHL
(Table 2). Further, no other IRF4 SNPs showed a statisti-
cally signiﬁcant association with overall NHL (Supple-
mentary Table 1).
Sun sensitivity and NHL. Lighter eye and hair color were
both statistically signiﬁcantly associated with decreased
NHL risk (Table 3). The associations were more pro-
nounced for eye color than hair color, and both associations
were consistent in analyses restricted to participants with
IRF4 genotype data and/or subjects self-reported as non-
Hispanic Caucasians. Hours in the mid-day sun in the last
10 years was also associated with decreased NHL risk.
Other markers of coloring and sun exposure and sensitivity
including skin complexion and reaction to ﬁrst sun of the
season were not associated with NHL risk.
IRF4 and sun sensitivity. Table 4 shows associations
between the two a priori IRF4 SNPs of interest
(rs12203592 and rs12211228) and measures of sun sensi-
tivity and sun exposure among non-Hispanic Caucasian
population controls. Presence of the variant allele in the
IRF4 SNP rs12203592 was associated with eye color and
hair color. The association between hair color and the IRF4
rs12203592 SNP was most pronounced with increasingly
light hair color. Compared to dark brown eyes, the mag-
nitude of association was equivalent for all other eye colors
which were strongly associated with the IRF4 rs12203592
variant allele. Curiously, the association between IRF4
rs12203592 with hair color and eye color appear to be in
opposite directions; this is consistent with the original
GWAS results from Han et al. [17] though was not further
explored.
The IRF4 rs12211228 SNP that was associated with
NHL was not statistically signiﬁcantly associated with any
of the measures of sun sensitivity or sun exposure in this
study (Table 4). All results were consistent in analyses
1294 Cancer Causes Control (2009) 20:1291–1302
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for race/ethnicity.
The remaining IRF4 SNPs evaluated were not found to
be statistically signiﬁcantly associated with measures of
sun sensitivity (data not shown).
Joint effects of IRF4 and sun sensitivity in NHL risk.
Table 5 shows the joint effects between eye and hair color
and NHL risk for the two a priori IRF4 SNP genotypes.
We observed no statistically signiﬁcant p-interactions for
either the IRF4 rs12203592 or rs12211228 SNP with hair
color or eye color. However, the risk estimates for NHL
among individuals with lighter eye and hair color appeared
more pronounced in those with either variant IRF4 allele
than in those with the corresponding common homozygote
genotype. This is also observed in stratiﬁed analysis
(Supplementary Table 2) whereby associations with NHL
for eye and hair color appear more pronounced among
those with a variant IRF4 SNP. No joint effects with hair or
eye color were observed for the remaining thirteen IRF4
SNPs evaluated (data not shown).
Discussion
The independent associations observed in our data are
consistent with those previously published for sun sensi-
tivity and NHL [19], for IRF4 rs12203592 and hair color
[17], and for IRF4 rs12211228 and NHL [8], to which our
data contributed. Of note, the IRF4 rs12203592 SNP
associated with hair color was not associated with NHL,
and the IRF4 rs12211228 SNP associated with NHL was
not associated with hair color. The two IRF4 SNPs are
neither correlated nor in linkage disequilibrium with one
another (r
2=0.001, D’=0.04), and accordingly we found no
statistically signiﬁcant p-interactions between IRF4 SNPs,
measures of sun sensitivity such as hair color, and NHL
risk. We do note that although associations between hair
color and NHL risk were observed among those with and
without variant IRF4 rs12203592 or rs12211228 alleles,
the risk estimates were slightly more pronounced among
those with either variant IRF4 genotype. We, therefore,
cannot discount a possible interrelationship between the
IRF4 SNPs with sun sensitivity and NHL risk given our
relatively small sample size to evaluate joint effects. We
believe that further evaluation, such as in consortial set-
tings where adequate sample sizes are available to assess
joint effects, are needed to determine whether these two
pathways both function through immune mediation or
separately with one through immune mediation and one
through pigmentation.
The major strengths of this study include the use of
population-based selection for both cases and controls and
Table 1 Characteristics of NCI-SEER case–control study participants
Characteristic Controls NHL cases
n (%) n (%)
SEER registry
Detroit 139 (17) 197 (20)
Iowa 246 (30) 301 (30)
Los Angeles 199 (24) 234 (24)
Seattle 244 (29) 258 (26)
Sex
Male 443 (54) 536 (54)
Female 385 (47) 454 (46)
Age (years)
\50 203 (25) 277 (28)
50–59 177 (21) 235 (24)
60–69 285 (34) 311 (31)
70? 163 (20) 167 (17)
Race/Ethnicity
White, non-Hispanic 646 (78) 828 (84)
Black 112 (14) 64 (6)
Asian/other/unknown 70 (8) 98 (10)
Education
\12 years 77 (9) 98 (10)
12–15 years 485 (59) 611 (62)
16? years 266 (32) 280 (28)
NHL histology
DLBCL – 294 (30)
Follicular lymphoma – 246 (25)
Marginal zone lymphoma – 82 (8)
CLL/SLL – 101 (10)
Mantle cell lymphoma – 40 (4)
Lymphoplasmacytic lymphoma – 24 (2)
Burkitt lymphoma – 11 (1)
Mycosis fungoides/Se ´zary
syndrome
– 18 (2)
Peripheral T-cell lymphoma – 41 (4)
NHL, not otherwise speciﬁed – 133 (13)
DNA source
Blood 598 (72) 688 (69)
Buccal 230 (28) 302 (31)
Interview group
Group A* 461 (56) 547 (55)
Group B** 367 (44) 443 (45)
Total participants 828 990
CLL/SLL chronic lymphocytic leukemia/small lymphocytic lym-
phoma, DLBCL diffuse large B-cell lymphoma, NCI National Cancer
Institute, NHL non-Hodgkin lymphoma, SEER surveillance, epide-
miology, and end results
* Group A: extended medical history, use of illicit drugs, family
medical history in addition to core questions
** Group B: abbreviated medical history, allergies, hobbies, sun
exposure (including eye color and skin complexion), phone use, food
frequency questionnaire in addition to core questions
Cancer Causes Control (2009) 20:1291–1302 1295
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123the ascertainment of data on a range of measures designed
to assess sun sensitivity and sun exposure in study subjects.
Also, our study population reﬂects all three previously
reported independent associations at the basis of this
analysis, making it ideal for investigating potential joint
effects. Study limitations include lower sample sizes
available for some primary and secondary analyses
resulting from the split-sample design, which allowed for
Table 5 Joint effects of eye color and hair color (excluding red hair) and overall non-Hodgkin lymphoma risk with IRF4 genotype, among non-
Hispanic Caucasians
IRF4 SNP Exposure Genotype Controls All NHL OR (95% CI)* p-value p-interaction
n (%) n (%)
rs12203592 Eye color 0.5475
Dark brown CC 49 (15) 79 (20) 1.00 (Ref.)
CT/TT 6 (2) 17 (4) 1.66 (0.60, 4.55) 0.3259
Light brown CC 16 (5) 20 (5) 0.80 (0.37, 1.71) 0.5589
CT/TT 7 (2) 10 (3) 0.83 (0.29, 2.37) 0.7312
Hazel CC 41 (13) 49 (12) 0.74 (0.43, 1.29) 0.2944
CT/TT 27 (8) 20 (5) 0.44 (0.22, 0.88) 0.0204
Blue CC 89 (27) 99 (25) 0.69 (0.44, 1.11) 0.1241
CT/TT 47 (14) 54 (14) 0.71 (0.41, 1.22) 0.2118
Green/blue-green CC 29 (9) 30 (8) 0.58 (0.31, 1.11) 0.0991
CT/TT 14 (4) 16 (4) 0.67 (0.30, 1.52) 0.3356
Hair color 0.6251
Black/dark brown CC 112 (18) 160 (21) 1.00 (Ref.)
CT/TT 85 (14) 112 (14) 0.92 (0.63, 1.34) 0.6706
Medium brown CC 107 (17) 166 (21) 1.09 (0.77, 1.54) 0.6402
CT/TT 54 (9) 72 (9) 0.94 (0.61, 1.45) 0.7721
Light brown/dark blonde CC 141 (23) 174 (22) 0.85 (0.61, 1.18) 0.3330
CT/TT 40 (7) 32 (4) 0.55 (0.32, 0.94) 0.0282
Light blonde CC 62 (10) 58 (7) 0.65 (0.42, 1.01) 0.0546
CT/TT 11 (2) 6 (1) 0.36 (0.13, 1.00) 0.0496
rs12211228 Eye color 0.5878
Dark brown GG 44 (13) 67 (17) 1.00 (Ref.)
CG/CC 11 (3) 29 (7) 1.69 (0.76, 3.77) 0.2011
Light brown GG 15 (5) 23 (6) 1.04 (0.48, 2.25) 0.9121
CG/GG 8 (2) 7 (2) 0.54 (0.18, 1.63) 0.2710
Hazel GG 51 (16) 49 (12) 0.62 (0.36, 1.09) 0.0946
CG/GG 18 (6) 20 (5) 0.73 (0.34, 1.55) 0.4098
Blue GG 96 (29) 105 (27) 0.73 (0.45, 1.18) 0.1951
CG/GG 42 (13) 48 (12) 0.76 (0.43, 1.35) 0.3501
Green/blue-green GG 29 (9) 34 (9) 0.71 (0.38, 1.35) 0.3008
CG/GG 13 (4) 13 (3) 0.64 (0.27, 1.52) 0.3096
Hair color 0.3200
Black/dark brown GG 137 (22) 187 (24) 1.00 (Ref.)
CG/GG 61 (10) 86 (11) 1.03 (0.69, 1.54) 0.8772
Medium Brown GG 102 (17) 176 (23) 1.27 (0.91, 1.78) 0.1550
CG/GG 60 (10) 63 (8) 0.76 (0.50, 1.16) 0.2007
Light brown/dark blonde GG 124 (20) 146 (19) 0.85 (0.61, 1.18) 0.3219
CG/GG 57 (9) 60 (8) 0.76 (0.49, 1.17) 0.2066
Light blonde GG 50 (8) 46 (6) 0.65 (0.41, 1.04) 0.0727
CG/GG 23 (4) 18 (2) 0.58 (0.30, 1.13) 0.1094
CI Conﬁdence interval, NHL non-Hodgkin lymphoma, OR odds ratio, SNP single nucleotide polymorphism
* Adjusted for age, sex, and study center
1300 Cancer Causes Control (2009) 20:1291–1302
123the collection of sun exposure and sun sensitivity data in
only half of the participant pool. This decreased the study’s
power to detect signiﬁcant interactions. Additionally, the
relatively low participation and response rates for the study
increase the potential for selection bias in the sample.
We acknowledge that our data may not have detected a
joint effect because none existed, because of limited sample
size and power to detect a joint effect, or because of our
imperfect measures for both genotype and sun exposures,
whichmayhavebiasedourresultstowardthenull.TheIRF4
SNPs associated with NHL and hair color were originally
identiﬁed as part of a tagging algorithm and thus are con-
sidered markers of susceptibility. The SNPs evaluated are
thus surrogates and likely in linkage disequilibrium with the
causal SNP. In addition, the speciﬁc mechanism by which
sun sensitivity and sun exposure affects NHL risk is
unknownandthepigmentationphenotypessuchashaircolor
are considered surrogates for this measure. We, therefore,
cannot exclude the possibility that our null observations for
joint effects between IRF4 and sun sensitivity are due to our
having a poor surrogate marker for the causal factor(s).
Finally, we also cannot exclude the possibility that joint
effects may exist for speciﬁc NHL subtypes which we were
unable to evaluate due to small numbers in our study.
In summary, our data support that genetic polymor-
phisms in the immune regulatory gene IRF4 are linked to
both risk for non-Hodgkin lymphoma and to hair color and
other phenotypic measures of sun sensitivity and exposure.
Further evaluation of joint effects in independent and larger
populations is needed. If joint effects are shown, further
investigations to identify the mechanisms by which sun
sensitivity or exposure and IRF4 genes function to modu-
late risk for NHL are warranted.
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